Insights

Global expansion Curium’s 2030 vision to expand into Japan and China signals growing demand in Asia for radiopharmaceuticals and diagnostic/therapeutic solutions, presenting opportunities for regional distributors, local manufacturing partnerships, and regulatory-aligned supply agreements.

Therapy pipeline Recent acquisition of Abscint and planned radioligand therapy production lines in France indicate a broadened oncology pipeline including PET radiodiagnostics and Lu-177 based therapies, opening cross-sell possibilities to oncology centers and hospital networks seeking integrated diagnostic and therapeutic radiopharmaceuticals.

Resilient supply Investments to install multiple manufacturing lines in Indiana for backup and isotope production underscore a focus on supply resilience, providing a sales opening for customers prioritizing reliability, just-in-time delivery, and risk mitigation in nuclear medicine programs.

US market momentum Plans to launch Lutetium Lu-177 dotatate in the United States following favorable court outcomes create near-term opportunities to engage payer corridors, clinical sites, and distribution partners for a high-demand somatostatin receptor-positive NET therapy.

Cardiac imaging tie Reintroduction of Thallous Chloride TI-201 injections in the US for cardiac imaging highlights Curium’s capability to support imaging-centric protocols; potential cross-sell to cardiology imaging centers and radiology networks seeking proven radiopharmaceuticals for nuclear cardiology workflows.

Similar companies to Curium Pharma

Curium Pharma Tech Stack

Curium Pharma uses 8 technology products and services including Databricks, Microsoft Power Automate, Tableau, and more. Explore Curium Pharma's tech stack below.

Media & News

Curium Pharma's Email Address Formats

Curium Pharma uses at least 4 email formats:
Curium Pharma Email FormatsExamplePercentage
First.Last@curiumpharma.comJohn.Doe@curiumpharma.com
96%
Last.First@curiumpharma.comDoe.John@curiumpharma.com
2%
FirstLast@curiumpharma.comJohnDoe@curiumpharma.com
1%
First.MiddleLast@curiumpharma.comJohn.MichaelDoe@curiumpharma.com
1%

Frequently Asked Questions

What is Curium Pharma's phone number?

Minus sign iconPlus sign icon
You can contact Curium Pharma's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Curium Pharma's official website and social media links?

Minus sign iconPlus sign icon
Curium Pharma's official website is curiumpharma.com and has social profiles on LinkedIn.

How much revenue does Curium Pharma generate?

Minus sign iconPlus sign icon
As of October 2026, Curium Pharma's annual revenue is estimated to be $1B - $10B.

What is Curium Pharma's NAICS code?

Minus sign iconPlus sign icon
Curium Pharma's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Curium Pharma have currently?

Minus sign iconPlus sign icon
As of October 2026, Curium Pharma has approximately 2.3K employees across 5 continents, including Europe, North America and Asia. Key team members include Ceo Spain: A. J. C., Ceo, Curium International: C. F. and Ceo Pet Europe: B. W. Explore Curium Pharma's employee directory with LeadIQ.

What industry does Curium Pharma belong to?

Minus sign iconPlus sign icon
Curium Pharma operates in the Pharmaceutical Manufacturing industry.

What technology does Curium Pharma use?

Minus sign iconPlus sign icon
Curium Pharma's tech stack includes Databricks, Microsoft Power Automate, Tableau, AutoCAD, Amazon Web Services, HashiCorp Terraform, Brevo and ServiceNow.

What is Curium Pharma's email format?

Minus sign iconPlus sign icon
Curium Pharma's email format typically follows the pattern of First.Last@curiumpharma.com. Find more Curium Pharma email formats with LeadIQ.

When was Curium Pharma founded?

Minus sign iconPlus sign icon
Curium Pharma was founded in 2017.
Curium Pharma logo

Curium Pharma

Pharmaceutical ManufacturingMassachusetts, United States1001-5000 Employees

Curium Pharma, headquartered in Paris, France, is a pharmaceutical manufacturer and provider of radiopharmaceutical products within the nuclear medicine sector, employing about 1,000 to 5,000 people. The company develops, manufactures and distributes radiopharmaceuticals with a focus on cancer and ongoing exploration of new innovations. It is described as a global leader in nuclear medicine and has a 2030 strategic vision to become an oncology-focused nuclear medicine leader, including expansion into Japan and China and broader global rollout. Its current cancer focus includes Neuroendocrine Tumors (NETs) and PSMA-targeted therapy for prostate cancer, and it is pursuing AI applications to improve imaging quality and diagnostic accuracy. In 2026, Curium announced substantial investments in France, including upgrading its Saclay manufacturing site to establish a European production line for Lu-177-PSMA-I&T, with commitments around EUR 32 million.

Section iconCompany Overview

Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2017
Employees
1001-5000

Section iconFunding & Financials

  • $1B - $10B

    Curium Pharma's revenue is estimated to be in the range of $1B - $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.